Mode
Text Size
Log in / Sign up
N/A N=13 Randomized Double-blind Diagnostic

Metaplasticity Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change

Healthy

Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Percent Change in MEP Amplitude — 1.19; 1.06; 1.38 Percent Change

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
rTMS (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of New Mexico
Primary completion
Feb 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change in MEP Amplitude
1.19; 1.06; 1.38
SECONDARY
Cortical Silent Period
1.02; 1.01; 0.99
SECONDARY
Simple Reaction Time
1.01; 1.02; 1.02

Summary

The overall objective is to validate the methodology of a metaplasticity experimental design by assessing change in motor excitability after administration of priming transcranial direct current stimulation (tDCS) followed by repetitive transcranial magnetic stimulation (rTMS) in healthy human participants.

Eligibility Criteria

Inclusion Criteria

  • Must be at least 18 years of age (all genders, races, ethnicity)
  • Must have no current psychiatric or neurologic issues
  • Must not have any conditions listed in exclusion criteria
  • Must be fluent in English

Exclusion Criteria

  • History of major psychiatric illness
  • Actively using neuropsychoactive medication
  • Legal or mental incompetency
  • Substance use disorder, abuse or dependence, with active use within the last three months
  • Significant medical or neurological illness
  • Prior neurosurgical illness
  • Prior neurosurgical procedure
  • History of seizure
  • History of ECT or TMS treatment within the past there months
  • Presence of a pacemaker, implanted medical pump or device, metal plate, or metal object in skull or eye (including shunts, dental implants, facial tattoos with metallic ink)
  • Pregnant women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03304262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search